Infertility/ART/IVF

PCO/PCOS
Capsule The definition of PCO/PCOS has changed several times during the last 4 decades. Should we change it again?  Despite the better understanding the treatment remains a challenge.
Chairpersons Bart Fauser,  Netherlands
Defining the polycystic ovary: AMH or ultrasound?
Antonio La Marca, Italy
WHO consensus algorithm for management of anovulatory PCOS
New insights into the PCOS
Joop Laven, Netherlands
Does Cochrane reviews show any role for metformin in the management of PCOS?
Thomas Tang, UK
USE, ABUSE AND UNDERUSE OF PROCEDURES
Capsule IVF has seen many technologies that have come and gone, and were used and abused. What is the future of these technologies?
Chairpersons Joop Laven, Netherlands
Nikolaos Polyzos, Spain
ICSI: From the beginning to where we are today, are we abusing ICSI?
Gianpiero Palermo, USA
The end of freeze all?
IVM: The rise and fall and rise again of IVM?
Johan Smitz, Belgium
Achieving deliveries in primary ovarian insufficiency
Kazuhiro Kawamura, Japan
FIBROIDS AND IVF: CAN WE REACH CONSENSUS?
Capsule The current delay in family planning increases the chances of encountering fibroids and age-related infertility. Which conservative solutions do we have in hand? Despite over 250 studies, Cochran summary failed to prove that myomas, that were suspected to affect implantation and pregnancy, were reversed by myomectomy. More studies are needed, but do we have a new medical solution?
Chairpersons Yacoub Khalaf, UK
Jacques Donnez, Belgium
The impact of uterine fibroids on fertility
Nikolaos Polyzos, Spain
The alternative management of uterine fibroids in infertile patients
Nicole Sänger, Germany
Medical treatment of fibroids in infertile women
Antonio La Marca, Italy
IMPLANTATION FAILURE AND WHAT’S NEXT
Capsule Most of the time, the reason for repeated implantation failure (RIF) is not easily apparent. Despite recent advances in our understanding, we do not have good solutions in hand. After a few failures, physicians are expected to provide an explanation and change the treatment. However, the true definition of RIF is at question.
Chairpersons Frank Broekmans, Netherlands
Johan Smitz, Belgium
Dong Zi Yang, China
The endometrium in repeated implantation failure
Nick Macklon, UK
High-throughput single-cell RNA-seq analysis of the endometrium associated with recurrent pregnancy loss
Jan Brosens, UK
  Immunology and implantation
Nathalie Ledee, France
  Does RIF exist?
Edgardo Somigliana, Italy
Special COGI-RBMO countercurrent lecture
IVF outcomes over the years. Is LBR rising or declining? Why?
Norbert Gleicher, USA
CONTROL OVARIA STIMULATION
Capsule The first step in IVF is probably the most crucial and yet it varies so significantly in different centers as to prevent real comparisons. Many questions are still open despite years of studies. Why use more than 225 IU of FSH, and why not use hCG for luteal support? Should we report results of one-year outcome or keep it the usual way?
Chairpersons Norbert Gleicher, USA
Rene Frydman, France
Why do we think more eggs is better than less eggs? Is it in the quality only?
Ben Mol, Australia
Why still use FSH dosages over 225 IU?
Frank Broekmans, Netherlands
When hCG was the luteal support drug: Will it be the come-back kid?
Claus Yding Andersen, Denmark
Which outcome should be reported in IVF? Let’s move to a one-year outcome
Bart Fauser, Netherlands
ENDOMETRIOSIS ADENOMYOSIS
Capsule The debate continues if mechanical infertility should be treated surgically or medically.
Chairpersons Victor Gomel, Canada
Nikolaos Polyzos, Spain
Debate:  Ovarian endometrioma before infertility
Prefer IVF first
Edgardo Somigliana, Italy
Prefer surgery first
Jacques Donnez, Belgium
Uterine adenomyosis: Can surgery help?
Leila Adamian, Russia
  Artificial uterus
Mats Hellström, Sweden
ET AND LUTEAL SUPPORT
Capsule Implantation is the least effective stage of IVF. The holy grail is to differentiate the many factors involved in implantation and failure. Surely ET and luteal phases support are important, but often there is little evidence with many practices never proven.
Chairperson Edgardo Somigliana, Italy
Progesterone support: Are all progesterone’s similar? Is there an upper dose for progesterone?
  Adjuvant luteal support, other than progesterone, any proofs?
Basil Tarlatzis, Greece
Why are we not all TOP-performing in embryo transfer technique?
Mohamed Aboulghar, Egypt
MicroRNAs new generation test to explore implantation window
Samir Hamamah, France
GENETIC TESTING OF EMBRYOS
Capsule Genetics testing of embryos is increasing. However, the results remain highly controversial. What has been proven to be the value of PGT, rather than what has not? What are we missing when we offer it to all? What not?
Chairpersons Simon Fishel, UK
Pasquale Patrizio,
USA
Basil Tarlatzis,
Greece
DebateMitochondrial DNA (mtDNA) can serve as a biomarker of pre-implantation embryo viability
Pros: Dagan Wells, UK
Cons: Nathan Treff, USA
  Debate: PGT for all patients over 35. Is that the way to go?
Yes: Santiago Munne, USA
No:
IVF: LESS IS MORE?
Capsule Will we do better with less eggs, less technologies, less testing?
Chairpersons Rene Frydman, France
Norbert Gleicher,
USA
Victor Gomel,
Canada
  Risk of cancer in women and children after ART
  Only blastocyst transfer, no adds on (no time lapse, no PGT)
Pasquale Patrizio, USA
  One and done or more or less eggs? What is the best?
Samir Hamamah, France
  Selective outcome reporting and sponsorship in randomized controlled trials in IVF and ICSI
Fulco van der Veen, Netherlands
Oocyte donation
  Special COGI-RBMO countercurrent 40 years on:
Moving towards stratifying patient treatment and removing subjectivity from IVF practice
Simon Fishel, UK
RTD ON PROVEN AND UNPROVEN ART PROCEDURES
Capsule Panelist-Audience discussion on
Chairpersons Zion Ben Rafael, Israel
Bart Fauser, Netherlands
Panelists Frank Broekmans, Netherlands
Simon Fishel, UK
Norbert Gleicher, USA
Samir Hamamah, France
Pasquale Patrizio, USA
Edgardo Somigliana
, Italy

What evidence do we have that assisted hatching works?
What evidence do we have for the “augment” procedure?
What evidence do we have for stem cell replenishment in the ovary?
What evidence do we have for the value of endometrial scratching?
What evidence do we have that high dose FSH increases success?
What evidence do we have that the “only SET policy” will not affect success?
How strong are the evidences that of in vitro activation of follicles is a viable option for the future?
How strong are the evidences that DHEA / testosterone pretreatment can affect IVF results?
How strong are the evidences that platelet rich plasma – is ovarian rejuvenation possible?
SPECIAL COGI & ALPHA SOCIETY WORKSHOP SESSION: ARE WE MAKING ADVANCES IN THE LABORATORY?
Capsule Time lapse use is growing. What advantages does it provides? Can we improve embryo quality?
Time-Lapse: Useful algorithms or just nice videos?
Alison Campbell, UK
  Can artificial intelligence help to select viable embryos?
Cristina Hickman, UK
  What can be done to improve embryo culture?
Laura Rienzi, Spain
  Does laboratory design really matter?
Roger Sturmey, UK
SPECIAL COGI & ALPHA SOCIETY WORKSHOP SESSION: WHAT MAKES A GOOD EMBRYO?
 Chairperson Laura Rienzi, Spain
Self-organization of the human embryo
CRISPER editing of the human embryo
Does parental diet really matter?
What biomarkers are worth measuring?
Special COGI-RBMO countercurrent lecture:
Aneuploidy and mosaic embryos can be transferred
Siobhan Quenby, UK
SPECIAL COGI & ALPHA SOCIETY WORKSHOP SESSION: EXTENDED SCREENING
Capsule Global screening is increasingly used, but do we have evidence of its cost effectiveness? Why do we need to screen all donors?
Chairpersons Joyce Harper, UK
Rita Vassena,
Spain
Debate:  Global re-evaluation of genetic testing in-light of the most recent advancements
Evidences are still lacking
Pasquale Patrizio, USA
Evidences have been achieved
Laura Rienzi, Italy
Should we fully screen all donors or only if the male is a carrier?
Rita Vassena, Spain
  An update on reproductive genetics.  What does the future hold
Joyce Harper, UK
MOSAICISM
Capsule One of the limitations of PGT is the interpretation of mosaicism. While it was proven that mosaic embryos can be transferred and result in normal babies, the true meaning of the high rate of mosaicism found in PGT remains controversial. In a multilateral debate the authors will argue that Mosaicism is not an obstacle to PGT, that it is an obstacle and that it is overestimated.
Chairperson Rita Vassena, Spain
3-sided Debate
Mosaicism is another reason why PGS is ineffective

Mosaicism is not an obstacle for PGS to work
Santiago Munne, USA
PGS works and mosaicism is overestimated
Nathan Treff, USA
Genomic medicine for personalized IVF/ICSI cycle
Samir Hamamah, France
LOSS OF OVARIAN RESERVE – WHAT ARE THE OPTIONS?
Oogonial stem cells: Where are we now?
Progress with in vitro maturation
Advances in ovarian cryopreservation
Fertility sparing cancer surgery
HISTORY OF IVF: PART 1
Capsule Based on the book “The History of IVF”, to be published later this year for the occasion of 40 years anniversary, the authors, all pioneers in their respective countries, will present their experience and the development of IVF from bench to a huge interdisciplinary medical field which helps millions of patients, affecting many live and spilling over to the kingdom of endangered species. Read the book for more and to see the topics and speakers’ bios.
The early American experience
Alan DeCherney, USA
  The track to assisted reproduction: Animal to human IVF
Jacques Cohen, USA
  The early days in the UK: Steptoe, Edwards, Purdy and Bourn Hall
Peter Brinsden, UK
  The contributions from “down under”
Gab Kovacs, Australia
  Developments in Europe
Basil Tarlatzis, Greece
HISTORY OF IVF: PART 2
Capsule Based on the book “The History of IVF”, to be published later this year for the occasion of 40 years anniversary, the authors, all pioneers in their respective countries, will present their experience and the development of IVF from bench to a huge interdisciplinary medical field which helps millions of patients, affecting many live and spilling over to the kingdom of endangered species. Read the book for more and to see the topics and speakers’ bios.
Development of IVF in India
  The development of ovarian stimulation protocols for IVF
Colin Howles, Switzerland
  The development of microsurgery for infertility
  Research on ART families: A historical perspective
Susan Golombok, UK
  The commercialization of IVF in the UK
Tony Rutherford, UK

*The scientific program is subject to change.